COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Impact of HIV and Its Treatment on Reverse Cholesterol Transport

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00168233
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 20, 2012
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred

Brief Summary:
To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.

Condition or disease
HIV Infections

Layout table for study information
Study Type : Observational
Actual Enrollment : 44 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport
Study Start Date : June 2005
Actual Primary Completion Date : September 2010
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

No antiretroviral therapy for 12 months
Initiating ARV therapy with an NNRTI based regimen
Initiating ARV therapy with a PI based regimen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV infected patients naive to ARV therapy

Inclusion Criteria:

  • Male patients with HIV infection (3 groups of 50 patients each)
  • HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
  • HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
  • HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen

Exclusion criteria

  • Treatment with any form of lipid lowering drugs, including fish oils.
  • Body Mass Index greater than 27.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00168233

Layout table for location information
Australia, Victoria
Alfred Hospital and Baker Heart Research Institute
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
National Health and Medical Research Council, Australia
Layout table for investigator information
Study Director: Dmitri Sviridov, Dr Baker Heart Research Institute, Commercial Road, Melbourne
Principal Investigator: Jennifer Hoy, A/Prof Alfred Hospital, Melbourne, Vic 3004
Layout table for additonal information
Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred Identifier: NCT00168233    
Other Study ID Numbers: 54/05
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012
Keywords provided by Jennifer Hoy, The Alfred:
Treatment Naive
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases